MSK drugs

Question 1

neutrophil chemotactic agent

Answer 1

LTB4

Question 2

LTC/D/E4 function

Answer 2

broncho/vasoconstriction, contraction of SM, and increase in vascular permeability

Question 3

inhibits platelet aggregation and promotes vasodilation

Answer 3

PGI2

Question 4

MOA of ASA

Answer 4

irreversably inhibits COX, lowering synth of TXA2 and prosoglandins,

Question 5

use of ASA

Answer 5

low dose: inhibits platelet aggregation
Middle dose: antipyeretic/analgesic
high dose: anti-inflammatory

Question 6

Tox of ASA

Answer 6

gastric ulcers, tinnitus

chronic use: kidney issues, upper GI bleeding

Question 7

OD of ASA

Answer 7

hyperventalation, and resp alkalosis

Question 8

NSAIDS MOA

Answer 8

REVERSABLY inhibits COX, lowering synth of TXA2 and prosoglandins,

Question 9

Use of indomethacin (NSAID)

Answer 9

close PDA

Question 10

tox of NSAIDS

Answer 10

intersistial nephritis, gastric ulcer, renal ischemia

Question 11

advantages of COX-2 (celecoxib)

Answer 11

spares gastric mucosa

Question 12

disadvantages of COX-2

Answer 12

increased risk of thrombis (cardiac event), sulfa allergies

Question 13

-dronate class

Answer 13

bisphosphonates

Question 14

MOA od bisphoshonates

Answer 14

binds hydrooxyapatite in bone, inhibiting osteoclast activity

Question 15

use of bisphoshonates

Answer 15

osteoporosis, hypercalcemia, pagets dx of bone

Question 16

tox of biphosphonates

Answer 16

corrosive esophagitis, osteonecrosis of jaw (phossy jaw)

Question 17

chronic gout drugs

Answer 17

allppurinol, deboxustat, probencidm colchinine

Question 18

acute gout drugs

Answer 18

NSAIDS, glucocorticoids

Question 19

MOA of colchine

Answer 19

binds and stabilizes tublin to inhibit polymeraztion - imparing chemotaxis and degranulation

Question 20

probencid MOA

Answer 20

inhibits xanithine oxidase

Question 21

TNF-a decoy receptor

Answer 21

etanercept

Question 22

anti-TNF a monoclonal antibody

Answer 22

infliximab, adalimumab